1. Home
  2. TPCS vs INTS Comparison

TPCS vs INTS Comparison

Compare TPCS & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TPCS
  • INTS
  • Stock Information
  • Founded
  • TPCS 1956
  • INTS 2012
  • Country
  • TPCS United States
  • INTS United States
  • Employees
  • TPCS N/A
  • INTS N/A
  • Industry
  • TPCS Metal Fabrications
  • INTS Biotechnology: Pharmaceutical Preparations
  • Sector
  • TPCS Industrials
  • INTS Health Care
  • Exchange
  • TPCS Nasdaq
  • INTS Nasdaq
  • Market Cap
  • TPCS 29.7M
  • INTS 33.4M
  • IPO Year
  • TPCS N/A
  • INTS 2023
  • Fundamental
  • Price
  • TPCS $3.05
  • INTS $2.03
  • Analyst Decision
  • TPCS
  • INTS Strong Buy
  • Analyst Count
  • TPCS 0
  • INTS 3
  • Target Price
  • TPCS N/A
  • INTS $8.50
  • AVG Volume (30 Days)
  • TPCS 20.3K
  • INTS 27.7K
  • Earning Date
  • TPCS 01-21-2025
  • INTS 03-13-2025
  • Dividend Yield
  • TPCS N/A
  • INTS N/A
  • EPS Growth
  • TPCS N/A
  • INTS N/A
  • EPS
  • TPCS N/A
  • INTS N/A
  • Revenue
  • TPCS $33,182,059.00
  • INTS N/A
  • Revenue This Year
  • TPCS N/A
  • INTS N/A
  • Revenue Next Year
  • TPCS N/A
  • INTS N/A
  • P/E Ratio
  • TPCS N/A
  • INTS N/A
  • Revenue Growth
  • TPCS 6.44
  • INTS N/A
  • 52 Week Low
  • TPCS $2.85
  • INTS $1.50
  • 52 Week High
  • TPCS $5.95
  • INTS $5.94
  • Technical
  • Relative Strength Index (RSI)
  • TPCS 40.35
  • INTS 39.02
  • Support Level
  • TPCS $3.04
  • INTS $2.02
  • Resistance Level
  • TPCS $3.19
  • INTS $2.53
  • Average True Range (ATR)
  • TPCS 0.11
  • INTS 0.31
  • MACD
  • TPCS 0.00
  • INTS -0.03
  • Stochastic Oscillator
  • TPCS 4.76
  • INTS 27.46

About TPCS TechPrecision Corporation Common stock

Techprecision Corp manufactures metal fabricated and machined precision components and systems. It offers a full range of services required to transform raw materials into precision finished products. The company's products are used in markets including defense, aerospace, nuclear, medical, and precision industries. All of its operations and customers are located in the United States. The company have two wholly owned subsidiaries that are each reportable segments: Ranor and Stadco. Each reportable segment focuses on the manufacture and assembly of specific components.

About INTS Intensity Therapeutics Inc. Common stock

Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with major unmet medical need.

Share on Social Networks: